A biweekly summary of new trial data, guideline recommendations and expert opinion across diabetes care, run by Diabetes Knowledge in Practice (www.knowledgeinpractice.eu). This podcast is intended for healthcare professionals only.
Featuring interviews with leading experts from across the globe.
This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education.
Featuring an interview with Dr William Alazawi.
Non-alcoholic fatty liver disease (NAFLD) is of increasing concern among people with type 2 diabetes. This condition, where an abnormal amount of fat is stored in liver cells, is associated with non-alcohol steathepatitis (NASH), which in turn can progress to fibrosis, cirrhosis and liver cancer. This episode provides a quick overview of NASH in diabetes before Dr William Alazawi, clinical lead for NASH for the Bart's Health NHS trust, provides his recommendations for patients with abnormal liver function.
Featuring an interview with Professor Ronald Goldenberg.
An overview of the co-occurrence of obesity and diabetes. This includes the effects of bariatric surgery, the underlying genetic factors of obesity, and recommended treatment approaches. Professor Goldenberg discusses practical advice for working together with patients to achieve normalisation of body weight and blood glucose
Featuring an interview with Professor Carel le Roux
An overview of recent data regarding the renal effects of SGLT2 inhibitors, GLP-1 RAs and DPP-4s. After a 5 minute data summary, Professor Le Roux provides his insight in helping patients achieve multifactorial treatment targets.
An overview of new and recent data presented during ADA 2019. This includes:
REWIND - the CVOT for dulaglutide
CARMELINA - the CVOT for linagliptin
CAROLINA - an active comparison CVOT studying linagliptin vs glimepiride
PIONEER 6 - the CVOT for oral semaglutide
DECLARE-TIMI 58 - the CVOT for dapagliflozin
Featuring an interview with Professor Steve Bain.
A highlight of PIONEER trial results, released during ADA 2019. This includes:
PIONEER 2 - Oral semaglutide vs empagliflozin
PIONEER 3 - Oral semaglutide vs sitagliptin
PIONEER 4 - Oral semaglutide vs liraglutide
PIONEER 5 - Oral semaglutide in patients with established kidney disease
PIONEER 6 - The CVOT for oral semaglutide
Featuring an interview with Professor Steve Bain